Catalyst

Slingshot members are tracking this event:

AbbVie (ABBV) Phase 3 EXPEDITION-1 Results Evaluating Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection With Genotypes 1,2,4,5 or 6 and Compensated Cirrhosis

Source Link:
https://news.abbvie.com/news/press-releases/abbvies-investigational-pan-genotypic-ribavirin-free-regimen-glecaprevirpibrentasvir-gp-achieved-99-percent-svr12-rate-in-chronic-hepatitis-c-patients-with-compensated-cirrhosis.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 20, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Expedition-1, Glecaprevir, Pibrentasvir, Chronic Hcv Infection, Compensated Cirrhosis, International Liver Congress
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.